16 reports

  • Medicines for Malaria Venture, Key Competitors
  • Medicines for Malaria Venture Enters into Agreement with Cipla and Strides Arcolab
  • Malaria
  • Pharmaceutical
  • United States
  • Company Operations
  • GlobalData's company
  • SMALL MOLECULES TO INHIBIT DXR FOR MALARIA AND TUBERCULOSIS - DRUG PROFILE
  • SMALL MOLECULES TO INHIBIT HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE FOR MALARIA AND TUBERCULOSIS - DRUG PROFILE
  • Malaria
  • Research And Development
  • United States
  • World
  • Product Initiative
  • SMALL MOLECULES TO INHIBIT HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE FOR MALARIA AND TUBERCULOSIS - DRUG PROFILE
  • SMALL MOLECULES TO INHIBIT DXR FOR MALARIA AND TUBERCULOSIS - DRUG PROFILE
  • Malaria
  • Research And Development
  • United States
  • Product Initiative
  • Sanaria Inc.

The organization offers HIV and AIDS, influenza, malaria and tuberculosis care services.

  • Infectious Disease
  • Malaria
  • Vaccine
  • United States
  • GlobalData's company
  • DEC 02, 2016: ACCESS BIO RECIEVED A USD $3.7 MILLION GRANT FROM THE BILL & MELINDA GATES FOUNDATION

Although the CAAD s development programs are focused on improved diagnostic approaches for diseases such as malaria, HIV and tuberculosis, these efforts are also expected to yield significant advances in point-of-care testing for infections that burden high-income countries, such as influen

  • Infectious Disease
  • Malaria
  • Molecular Diagnostic
  • South Korea
  • GlobalData's company
  • GENVEC ENTERS INTO RESEARCH AGREEMENT WITH LMIV

The institute' s research areas include infectious diseases such as tuberculosis and influenza, HIV/ AIDS, biodefense; and immune-mediated diseases including asthma and allergy.

  • Healthcare
  • Malaria
  • Pharmaceutical
  • United States
  • GenVec, Inc.
  • FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS PIPELINE PRODUCTS BY INDICATION
  • FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS, MAJOR PRODUCTS AND SERVICES
  • Diagnostics
  • Infectious Disease
  • Malaria
  • Africa
  • GlobalData's company

HIV/ AIDS is the leading cause of deaths of over ##. ## million people every year; and malaria and tuberculosis together cause deaths of an estimated ##. ## million people.

  • Gene Therapy
  • Malaria
  • Vaccine
  • United States
  • GenVec, Inc.
  • DEC 02, 2016: ACCESS BIO RECIEVED A USD $3.7 MILLION GRANT FROM THE BILL & MELINDA GATES FOUNDATION

Although the CAAD s development programs are focused on improved diagnostic approaches for diseases such as malaria, HIV and tuberculosis, these efforts are also expected to yield significant advances in point-of-care testing for infections that burden high-income countries, such as influen

  • Infectious Disease
  • Malaria
  • Molecular Diagnostic
  • South Korea
  • GlobalData's company

EISAI ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH BROAD INSTITUTE FOR NEGLECTED TROPICAL DISEASES AND TUBERCULOSIS Eisai Enters Into Co-Development Agreement With Broad Institute For Neglected Tropical Diseases And Tuberculosis Eisai Co., Ltd., a healthcare company, entered into a gl

  • Cancer
  • Malaria
  • Japan
  • United States
  • Eisai Co., Ltd.
  • INFECTION DETECTION TEST - P. FALCIPARUM - PRODUCT STATUS
  • INFECTION DETECTION TEST - P. FALCIPARUM - PRODUCT DESCRIPTION

FIND also provides malaria therapy programs, neglected tropical diseases therapy programs, tuberculosis therapy programs, HIV therapy programs, and cross-cutting themes solutions.

  • Clinical Trial
  • Malaria
  • Point Of Care Testing
  • United States
  • GlobalData's company
  • Cellceutix Corporation - Dormant Developmental Projects,2016
  • Malaria
  • R&D
  • Research And Development
  • United States
  • Cellceutix Corporation
  • Official Title
  • Clinical Trial Profile Snapshots

Tuberculosis Treatment in African Patients Evaluating Pharmacokinetic Interactions Between Artemisinin-based Therapies and Rifampicinbased Tuberculosis Treatment in African Patients GDCT## PACTR##, HS## Infectious Disease Malaria, Tuberculosis Completed

  • Clinical Trial
  • Infectious Disease
  • Malaria
  • World
  • GlaxoSmithKline plc
  • DESIGNMEDIX ENTERS INTO AGREEMENT WITH THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

The institute' s research areas include infectious diseases such as tuberculosis and influenza, HIV/ AIDS, biodefense; and immune-mediated diseases including asthma and allergy.

  • Malaria
  • United States
  • Company
  • Deals & Alliance
  • DesignMedix
  • Eisai Co., Ltd. - Discovery, 2016
  • Malaria
  • R&D
  • Research And Development
  • United States
  • Eisai Co., Ltd.
  • THROMBOSIS
  • ASTRAZENECA PLC - DISCOVERY, 2016

The scientists reported ##, ##-azaindoles as a new inhibitor class that killed Mycobacterium tuberculosis in vitro and demonstrated efficacy in mouse tuberculosis models.

  • Cancer
  • Malaria
  • Therapy
  • United States
  • AstraZeneca PLC